Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical and medical technology company focused on the development of light-activated therapies for the treatment of cancer and other diseases. The company operates primarily in the oncology therapeutics and medical laser technology industries, combining proprietary drug formulations with laser systems to enable photodynamic therapy (PDT). Its activities are publicly reported through Canadian regulatory filings and investor disclosures, as the company is listed on the TSX Venture Exchange and trades in the United States on the OTC market under the symbol TLTFF.
The company’s core value proposition centers on its lead drug candidate Ruvidar® (TLD-1433), which is being developed for the treatment of non-muscle invasive bladder cancer (NMIBC), including cases that are unresponsive to standard Bacillus Calmette–Guérin (BCG) therapy. Theralase was founded in the early 2000s as a laser technology company and later transitioned into oncology drug development, evolving its strategy to integrate pharmaceutical innovation with specialized light-delivery systems as a differentiated therapeutic platform.
Business Operations
Theralase operates through two primary business segments: Drug Development and Laser Technology. The Drug Development segment is the company’s principal revenue and value driver, focused on advancing Ruvidar® (TLD-1433) through clinical trials for bladder cancer indications. This segment encompasses preclinical research, clinical trial management, regulatory engagement, and intellectual property development related to light-activated compounds.
The Laser Technology segment involves the design and manufacture of low-level laser therapy (LLLT) and therapeutic laser systems, which historically generated commercial revenue and continue to support the company’s PDT platform. Operations are conducted primarily in Canada, with clinical trial activities extending into the United States through collaborations with clinical research sites. Based on publicly available disclosures, the company does not report material operating subsidiaries or joint ventures; activities are conducted directly by Theralase Technologies Inc. Data inconclusive based on available public sources regarding long-term commercial partnerships beyond clinical trial collaborations.
Strategic Position & Investments
Strategically, Theralase is focused on advancing Ruvidar® (TLD-1433) toward regulatory approval, positioning the drug as a potential alternative treatment for bladder cancer patients who have limited options following BCG failure. Growth initiatives are centered on completing Phase II clinical trials, engaging with regulatory authorities, and preparing for later-stage development contingent on trial outcomes. The company’s strategy emphasizes unmet medical needs in oncology where localized, light-activated therapies may offer safety or efficacy advantages.
The company’s investment activity is primarily internal, allocating capital toward clinical development, intellectual property protection, and refinement of its laser delivery technologies. Theralase has not disclosed any material acquisitions of other companies in recent public filings. Its emerging technology focus remains on photodynamic oncology applications, with potential future expansion into additional cancer indications if supported by clinical data. Any diversification beyond bladder cancer remains data inconclusive based on available public sources.
Geographic Footprint
Theralase Technologies Inc. is headquartered in Canada, with its corporate offices and core research activities located in Ontario. The company maintains a primary operational presence in North America, reflecting its focus on Canadian and U.S. regulatory pathways and healthcare markets.
Internationally, Theralase’s footprint is limited and largely tied to clinical and investor-facing activities rather than commercial operations. Clinical trials for Ruvidar® (TLD-1433) have involved sites in both Canada and the United States, providing the company with cross-border clinical exposure. There is no verified public disclosure of significant operational facilities, manufacturing plants, or commercial infrastructure outside North America.
Leadership & Governance
Theralase is led by an executive team with experience in medical technology commercialization, clinical development, and corporate governance. Leadership has articulated a strategic vision centered on disciplined clinical execution, regulatory compliance, and long-term value creation through oncology-focused innovation. Governance practices are aligned with requirements applicable to Canadian public companies listed on the TSX Venture Exchange.
Key executives include:
- Roger Dumouchel – President & Chief Executive Officer
- Robert Fife – Chief Financial Officer
- Glen Koren – Director
Additional executive or scientific leadership roles have been referenced in public disclosures at various times; however, consistent verification of titles and tenure beyond the individuals listed above is data inconclusive based on available public sources.